Arbutus Biopharma Secures $950M Moderna Settlement, Reports Strong Q4/FY25 Results, and Advances HBV Program

summarizeSummary

Arbutus Biopharma announced a major $950 million upfront settlement with Moderna for LNP patent infringement, significantly boosting its financial position and prompting consideration of shareholder capital return, alongside reporting improved Q4/FY25 financials and positive clinical trial results for imdusiran.

check_boxKey Events

• Landmark Moderna Settlement

  Arbutus and Genevant reached a global settlement with Moderna for LNP patent infringement, including a $950 million non-contingent payment in July 2026 and a contingent $1.3 billion. Arbutus is entitled to 20% of the non-contingent payment after litigation costs.

• Strong Financial Position

  The company reported $91.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025, with a reduced net loss of $33.5 million for the year, reflecting successful cost-cutting and restructuring efforts.

• Shareholder Capital Return Under Consideration

  Following the significant settlement, Arbutus is evaluating a return of capital to shareholders in Q3 2026.

• Positive Clinical Progress for Imdusiran

  Two additional patients in Phase 2a clinical trials for imdusiran achieved functional cure in chronic hepatitis B, bringing the total to 10 patients to date.

auto_awesomeAnalysis

This 8-K announces a landmark global settlement with Moderna, providing Arbutus with a significant non-contingent payment of $950 million (with Arbutus receiving 20% after litigation costs) and a contingent payment of $1.3 billion. This substantial financial infusion dramatically strengthens the company's balance sheet and cash runway, leading the company to evaluate a return of capital to shareholders. Concurrently, Arbutus reported improved financial results for Q4 and FY 2025, driven by cost-cutting and reduced net loss, alongside positive clinical progress for its lead HBV candidate, imdusiran, with two additional patients achieving functional cure. The settlement de-risks the company's financial future and provides substantial resources for its clinical programs.